Hodgkin's Lymphoma News and Research RSS Feed - Hodgkin's Lymphoma News and Research

Hodgkin's lymphoma, previously known as Hodgkin's disease, is a type of lymphoma, which is a type of cancer originating from white blood cells called lymphocytes. It was named after Thomas Hodgkin, who first described abnormalities in the lymph system in 1832.
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology. [More]
Non-Hodgkin lymphoma subgroups found to have different survival rates

Non-Hodgkin lymphoma subgroups found to have different survival rates

A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood. [More]
Researchers identify two oncogenes that drive the development of medulloblastoma

Researchers identify two oncogenes that drive the development of medulloblastoma

A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute, UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children. [More]
Cancer drug offers protection against thrombosis

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots. [More]
Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology. [More]
HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap. [More]
MRI detects invasive breast tumours at very early stages in survivors of childhood Hodgkin lymphoma

MRI detects invasive breast tumours at very early stages in survivors of childhood Hodgkin lymphoma

The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma (HL), who are at increased risk because they received chest radiation, shows that magnetic-resonance imaging (MRI) detected invasive breast tumours at very early stages, when cure rates are expected to be excellent. [More]
Alligator Bioscience acquires rights to drug development candidate ADC-1013

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]
Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology. [More]
Researchers discover how of EBV virus takes over human cells gene regulating machinery

Researchers discover how of EBV virus takes over human cells gene regulating machinery

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself. [More]

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma. [More]
University of Montreal scientists discover molecular details of kissing disease virus attacks

University of Montreal scientists discover molecular details of kissing disease virus attacks

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself. [More]
Menopausal hormone therapy may lower risk of B-cell non-Hodgkin lymphoma

Menopausal hormone therapy may lower risk of B-cell non-Hodgkin lymphoma

Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma. [More]
Helium ion radiotherapy provides hope for improved, accurate radiation treatment for young cancer patients

Helium ion radiotherapy provides hope for improved, accurate radiation treatment for young cancer patients

For the first time, researchers have been able to demonstrate that the use of helium ions in radiation therapy could provide accurate treatment to tumours while helping to spare healthy organs. [More]
FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL). [More]
Einstein faculty members present recent research at AACR Annual Meeting

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year. [More]
EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. [More]